ArticleCureus2026
Rare Leukemic Phase of Follicular Lymphoma With a High-Risk Follicular Lymphoma International Prognostic Index (FLIPI) Score Treated With Bendamustine-Rituximab.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma is a slow-growing B-cell non-Hodgkin lymphoma, accounting for approximately 20 to 30% of global cases. The leukemic phase is a rare presentation. It is often associated with high-risk characteristics, high tumor burden, slow progression, diagnostic challenges, and unfavorable prognosis. Risk stratification using the Follicular Lymphoma International Prognostic Index (FLIPI) is crucial, since individuals classified as high-risk (FLIPI ≥3) have aggressive disease with inferior progression-free and overall survival outcomes. We report a case of a 51-year-old woman with extensive lymphadenopathy and leukocytosis, subsequently diagnosed with the leukemic phase of follicular lymphoma, with a FLIPI score of 3. She was treated with bendamustine and rituximab (BR regimen), along with supportive prophylaxis and growth factor support. The patient tolerated six cycles of the BR regimen with clinical enhancement and hematological stability. This case report emphasizes the pivotal role of integrating timely diagnostic evaluation, accurate risk stratification, and early incorporation of risk-adapted contemporary chemoimmunotherapy approaches in the management of the leukemic phase of follicular lymphoma, collectively leading to favorable patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.